Khiron Life Sciences (TSX.V: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC) (“Khiron” or the “Company”) is a vertically integrated cannabis leader with core operations in Latin America and Europe. The company trusts in the vast benefits of medical cannabis and is committed to improving the life quality of patients and consumers through the applied use of cannabis and technology. Khiron is licensed in Colombia for the cultivation, production, domestic distribution, and international export of both low and high THC medical cannabis products, having achieved first sales in March 2020 and medical cannabis insurance coverage in December 2020. Additionally, the Company has commenced medical cannabis sales in the United Kingdom, Peru, and Germany, with Mexico and Brazil also anticipated this year. Khiron operates six wholly owned health centres in Colombia, where it completed more than 100,000 patient transactions in 2020. The Company is currently expanding patient access in Latin America through satellite clinics, with plans to accelerate growth in Europe by leveraging assets developed in Colombia, including clinical IP, genetics, and data. Khiron has successfully exported its registered cannabis strains, in the form of live clones, from Colombia to Europe. This significant milestone represents the first shipment of medical cannabis live plant material to Europe from Colombia and is expected to accelerate access to European markets. Tejinder Virk (Khiron’s European Managing Director and President) explains the process of certifying the company’s cannabis strains for export to Europe by way of clones: “A clone is a cannabis plant that is a genetic copy of a mother plant. These clones were cut from our THC and CBD bearing mother plants in Colombia, which are used to make medicines for thousands of our patients in Latin America (over 10,000 prescriptions to date and growing quickly!). Europe has a population of nearly 748 million people and there is enormous patient need for cannabis-based medicines. However, doctors in Europe need solid clinical evidence to confidently prescribe medical cannabis for ailments such as pain, sleep or anxiety. By replicating our Colombian magistrals as EU GMP certified medicines, we aim to provide European doctors with practical clinical evidence from Colombia. This will also help ensure European patients get safe and efficacious treatment. The achievement demonstrates our global regulatory leadership and ability to export our intellectual property to other markets.” As the management team executes its growth strategy throughout the United Kingdom and Germany by introducing branded extracts and dried flower products, Khiron continues to validate its patient-centric strategy with over 13,000 prescriptions written to date amid plans to reach 1 million patients and consumers by 2024. Most recently, the first shipment of Khiron-branded EU-GMP certified cannabinoid-based medicine was successfully completed, providing immediate access to the German market through Khiron’s distribution partner, Nimbus Health GmbH, a leading EU-GMP/GDP certified medical cannabis distributor in Germany, with a network of over 300 pharmacies. Khiron teams continue to educate physicians with plans to leverage clinical evidence from both the UK and Colombia. This major milestone represents a new revenue stream for Khiron and positions Khiron’s European team to execute on its German medical strategy. As a revolutionary, patient-focused, global leader of medical cannabis from Latin America, Khiron offers products that are manufactured in GMP-GEP compliant facilities in Colombia and are standardized and stabilized according to the U.S. Pharmacopeia analytics standard (USP42). Khiron believes, with its extremely skilled management team, that the company will be a frontrunner in the global medical cannabis market, which is expected to reach $44 billion by 2024 (https://ibn.fm/WnVpJ) and $84 billion by 2028 (https://ibn.fm/zqm2Z).

• Mohawk Group Holdings Inc. reported a 62.3% increase in its 2020 revenue compared to 2019
• It earned a revenue of $185.7 million, and its earnings guidance show that this figure will grow by a further 88% to 105% in 2021
• This growth is thanks to the company’s acquisition strategy, which has expanded its list of brands to eleven and it is still targeting more companies
• The acquisition strategy is, however, problematic in a few ways

Mohawk Group Holdings (NASDAQ: MWK) finished the financial year ended December 31, 2020, on a high note reporting $185.7 million in revenue, an increase of 62.3% or $71.3 million compared to a similar period in 2019, backed by an impressive fourth-quarter performance, which included improved profitability, strong growth in sales and revenue, and boosted guidance, as highlighted in a recent Motley Fool article titled “Mohawk Just Wrapped Up a Perfect 2020” (https://ibn.fm/fl95B). This 62.3% revenue increase marked a consistent trend year-on-year for the two most recent reporting periods, given that it reported a growth in revenue of 56.2% in 2019 compared to 2018. Notably, this upward trajectory is likely to continue as its earnings guidance for 2021 indicates that the revenue will grow by between 88% and 105%, buoyed by potential mergers and acquisitions. “We are currently evaluating a strong pipeline of potential M&A targets that in total have trailing twelve month’s net revenue of $522 million and trailing twelve month’s EBITDA of $97 million,” said co-founder and chief executive officer Yaniv Sarig during the release of the 2020 annual report (https://ibn.fm/Z4eJ7). The acquisition strategy, which Mohawk uses only if it believes purchasing a brand is more advantageous than developing its own brands and products, has grown its portfolio to 11 brands that sell products in multiple categories and based on Yaniv’s assertions, it is unlikely to be discontinued. In Q4 of 2020 alone, for example, Mohawk Group spent more than $100 million in cash and stock to purchase five separate e-commerce brands, including $48 million on Healing Solutions, which owns an extensive essential oils and wellness portfolio. However, the strategy has a few issues and limitations. To shareholders, the dilution of shares is inevitable, as Mohawk usually acquires companies using cash and some of its stock. Secondly, new additions could potentially disrupt the company’s core operations and adversely affect its operating results as a result. Thirdly, the impacts of these newly acquired companies on the company’s profitability are not immediate. And this is made clear by looking at the company’s 10-K filing with the SEC. According to the report, Mohawk reported a net loss of $63.1 million, down from $58.8 million in 2019 (https://ibn.fm/zMiqm). This is due, in part, to how the acquisition works. “Once it acquires a brand, the brand typically runs at a loss until its products generate enough ratings and reviews to sell organically” (https://ibn.fm/CSYSH). This is on top of the fact that high competition on the e-commerce platforms could again reduce MWK’s chances of realizing any profits from the products and brands. Fortunately, to deal with such problems, Mohawk could rely on its proprietary AIMEE platform. AIMEE allows MWK to identify product and market opportunities and to execute and manage online marketing strategies. Additionally, it enables the company to increase its products’ and brands’ value propositions by relying on data-driven approaches applicable throughout the entire consumer product value chain. The company believes that by scaling AIMEE, it will gain “purchasing power both at the product level and at the overall fulfillment level,” which will improve its operating results, per its 10-K filing. Although the company’s profitability depends on a few factors that the company may not immediately control, Mohawk is focused on providing shareholder value through other avenues, including more acquisitions and the improvement of its AIMEE platform. Based on the earnings guidance, 2021 looks set to be an equally impressive year for Mohawk. For more information, visit the company’s website at www.Mohawkgp.com. NOTE TO INVESTORS: The latest news and updates relating to MWK are available in the company’s newsroom at https://ibn.fm/MWK

• Rapidly positioning itself as a multi-state operator, Hero Technologies Inc. holds a portfolio of subsidiaries with strategic operations within the cannabis industry
• The company currently has a multi-state vertical business model that includes cannabis genetic engineering, farmland for medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, retail operations and dispensaries
• Hero Technologies plans to expand on the proprietary, solar-powered aeroponic cannabis cultivation system of BlackBox Systems and Technologies, as it could help lower the industry’s carbon footprint
• The company’s management team is comprised of financial industry veterans who have a combined history of mergers, acquisitions and overall company development
• North America provides the largest revenue share in the cannabis industry, accounting for 91.1% of the global market in 2020; the continent also has the highest number of CBD businesses globally
• Hero Technologies is currently expanding into the Colorado and Massachusetts cannabis markets via two wholly owned subsidiaries

Hero Technologies (OTC: HENC) is a cannabis company with a vertically integrated business model and plan that includes cannabis genetic engineering, farmland for medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, retail operations and dispensaries that make the organization a multi-state operator (“MSO”). The company was founded in 2004 and is headquartered in Dover, Delaware. Portfolio The company holds the majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation firm focused on providing optimal conditions to enhance photosynthesis and cultivation. Hero Technologies is planning expansion in cultivation and dispensary operations in Colorado through wholly owned subsidiary Mile High Green LLC, while expansion in Massachusetts is planned through another wholly owned subsidiary, MassCannabis LLC. Hero Technologies also owns and operates HighlyRelaxing.com under Highly Relaxing LLC and recently acquired the assets of V Brokers LLC, now operating as Veteran Hemp Co. at VeteranHempCo.com. BlackBox Systems and Technologies LLC BlackBox Systems and Technologies LLC markets a proprietary cannabis aeroponic cultivation system designed for the large-scale production of top-shelf cannabis products. BlackBox offers the optimal conditions to enhance photosynthesis and promote the cultivation of large flowering plants. The system’s dry room, process room and secure storage were designed for precise control through each phase of the cannabis lifecycle. Weekly harvests are achieved using 13 separate BlackBox systems in independent modules. The system provides a series of key benefits, including:

• High-pressure nutrient delivery, with no nutrient or PH deficiencies
• Sterile, 100% nutrient solution
• Drain to Waste (no reuse of wastewater)
• Low water usage (1 gallon per plant per day)
• Constant PH and EC in reservoirs
• Modular design (1 to 100 pods in any configuration)
• Innovative proprietary engineering
• Minimal cleanup
• Media-less growing, suspended in the air, with no media waste
• No pesticides

Highly Relaxing LLC Highly Relaxing LLC is an emerging Henderson, Nevada-based operation dedicated to providing customers with honestly labeled, high-quality hemp-derived CBD products. Its current offerings include a topical CBD cream that provides localized relief from potential discomfort. Veteran Hemp Co. Veteran Hemp Co.’s mission is to provide a quality, consistent and delicious product for Americans looking to enjoy the hemp smoking experience. Its product is brought in by only the finest farming operations delivering the best genetics. Veteran Hemp Co. has its own custom harvest plans, drying facilities and all of the logistics that fall between. Veteran Hemp Co. prides itself on being a veteran-approved company. Market Outlook The global legal cannabis market is anticipated to reach $84 billion by 2028, expanding at a CAGR of 14.3% from 2021 to 2028. The driving factor for this forecast expansion is the increasingly widespread legalization of cannabis for medical and recreational use. Recreational use accounted for 60.3% of industry revenue in 2020. North America provided the largest revenue share in the cannabis market, accounting for 91.1% of the global market in 2020. Due to the early legalization of medical and recreational cannabis in the region, the customer pool has increased exponentially (https://ibn.fm/2L9xN). The global CBD market was valued at $2.8 billion in 2020 and is expected to grow at a CAGR of 21.2% and reach $13.4 billion by 2028. North America is considered the most progressive region for cannabis and its derived products, with the highest number of CBD companies being based on the continent. The B2B (business to business) segment dominates the CBD industry, accounting for the largest revenue share at 59.6% in 2020 (https://ibn.fm/OD1YQ). With its vertically integrated business model and development into a multi-state operator across multiple sectors of the cannabis industry, Hero Technologies is uniquely positioned to capitalize on the fast-growing market and the growing number of opportunities emerging as a result of legalization and increased popularity among consumers. Management Team Gina Serkasevich, CPA, CMA, is the Chief Executive Officer, Treasurer and Secretary of the Hero Technologies. She previously worked for Holloman Corporation as its Director of Finance beginning in June 2012 and was appointed Chief Financial Officer of Holloman Energy Corporation in August 2014. She has more than 30 years of domestic and international corporate accounting and finance experience. She served as U.S. Controller for EFLO Energy Inc., a company focused on the acquisition, exploration and development of oil and gas assets in North America. Prior to 2012, Ms. Serkasevich worked in the oil and gas tanker transportation industry as a Regional Financial Manager for AET Inc. Limited (2011-2012), as a Financial Consultant for OSG Ship Management Inc. (2009-2011) and as a Financial Controller/CFO for Stena Bulk LLC (1998-2008). During her 11-year tenure at Stena Bulk LLC, she established the financial, accounting and reporting requirements for its new joint ventures and tanker pools with Sonanagol USA and held the Company Secretary position on both of those companies’ boards of directors. Dan McCarthy is the company’s Corporate Development Manager. He has spent more than 12 years in the institutional investment community, holding various investment banking and private equity executive roles. Thus far, he has been a part of over $1 billion in transactional value ranging from debt and equity to acquisitions and diversities throughout his career. Mr. McCarthy’s most recent role was Managing Director at Petro Capital, a Dallas-based private equity and investment bank. He began his career working for a private international consulting firm based in Washington, D.C., helping corporations and funds expand into non-G7 countries utilizing World Bank financing. He is also a graduate of the University of Kansas School of Business and completed the Mergers and Acquisitions program at the New York Institute of Finance. James Rowland is Hero Technologies’ Marketing Advisor and an expert in marketing and e-commerce. He has held many high-level marketing and business-related roles. He is the Founder and current CEO of PerfectCheckout.com and the current Business Development Specialist at Fulfillment.com. Mr. Rowland has held multiple high-level positions throughout his career, which have provided him with the experience needed to bring success-backed marketing leadership skills to his current role with the company. For more information, visit the company’s website at www.HeroTechnologiesInc.com. NOTE TO INVESTORS: The latest news and updates relating to HENC are available in the company’s newsroom at https://ibn.fm/HENC

• The AmpliTech management team is led by Founder, President, CEO, and CTO Fawad Maqbool, who has been in the microwave industry for over 30 years
• AmpliTech’s current catalog of devices is substantial, and it is always growing and adapting to include new technology
• Currently, the company’s target markets include 5G/6G infrastructures, AR/VR, Cyber Security, Military/Defense, SATCOM, Autonomous Self-Driving Vehicles, and more
• Current AmpliTech product offerings support a frequency range of 50 kHz to 44 GHz, with plans to eventually offer designs up to 100 GHz
• The global microwave devices market was valued at $7.44 billion in 2019 and is expected to reach $9 billion by 2025, growing at a CAGR of 3.23%

AmpliTech Group (NASDAQ: AMPG, AMPGW) designs, develops and manufactures custom radio frequency (“RF”) components for the commercial, SATCOM, space and military markets. In addition to developing new products for the 5G/6G wireless ecosystem and infrastructure, the company has placed focus on the development of leading-edge solutions in quantum computing in support of U.S. efforts to reach the coveted position of quantum supremacy. The company maintains a commitment to R&D that allows it to remain at the forefront of emerging technologies. AmpliTech aims to use its advanced techniques and IP to provide tomorrow’s technology today, improving everyone’s quality of life. AmpliTech was founded by Fawad Maqbool in 2002 to fill the need for affordable, high-quality, customized and state-of-the-art amplifiers and components. Headquartered in Bohemia, New York, the company currently has distributors and representatives available worldwide. Product Portfolio AmpliTech’s mission is to develop quality, state-of-the-art microwave amplifiers by leveraging its experience, proven technical expertise and superior design heritage. The company’s products cover a frequency range from 50 kHz to 44 GHz, with plans to eventually offer designs up to 100 GHz. Its current catalog includes: Amplifiers

• Low Noise Amplifiers
• Cryogenic Amplifiers
• Limiting Amplifiers
• Waveguide Amplifiers
• Medium/High Power Amplifiers
• Surface Mount Amplifiers

Passive Components

• End Launch Rectangular Adapters
• Rectangular Adapter to COAX
• Power Dividers

All the company’s products come with a satisfaction guarantee, as the company is fully committed to providing only high-quality products free from manufacturing and material defects and guaranteed to perform according to applicable specifications. Consulting Services Leveraging more than 100 years of combined experience in microwave systems and component design ranging from active components to passive devices, AmpliTech also provides valuable consulting services and technical assistance to its customers. With capabilities ranging from initial design to final manufacturing and delivery, the company’s team also offers project management services and advice on both technical aspects and how to handle business issues such as resource allocation, customer contact, budget restraints, time limits and more. Other key benefits of AmpliTech consulting services that can give its customers a definitive edge include:

• Timely technical assistance
• Little or no learning curve
• Less long-term costs associated with full-time employees with benefits and salaries
• Availability when necessary
• Customer support with schedules, project management and on the job training
• Access to technology
• Partnering for manufacturing and/or complete turn-key product solution
• Personal guidance from concept to development
• Custom designs for each application

Market Outlook The global microwave devices market was valued at $7.44 billion in 2019 and is expected to grow at a CAGR of 3.23% and reach $9 billion by 2025 (https://ibn.fm/4K2zG). Governmental expenditures in the defense and space communications sectors are expected to expand the opportunities for growth within the industry. AmpliTech continues to follow its strategy of identifying key elements in today’s technological revolution. It is leveraging its technical expertise and experience to align product portfolios and IP with innovation (https://ibn.fm/HOxeY). The company has plans to be a catalyst in the enhancement, development and distribution of breakthroughs in the following sizeable markets:

• High Speed Terrestrial and Satellite Terminals (SATCOM, “Internet in the Sky”)
• 5G/Wi-Fi6E and 6G wireless infrastructure (Cellular Base Stations, Small Cells, Private Wi-Fi Networks)
• IoT (Internet of Things)
• Cloud Farms, Big Data and MEC architecture
• Quantum Supercomputers/Quantum Research
• Deep Space Astronomy
• Autonomous Self-Driving Vehicles
• Telemedicine, AR/VR (Augmented and Virtual Reality)
• Drones, UAVs (Unmanned Aerial Vehicles)
• Cyber-security
• Military/Defense ECM/EW

Management Team Fawad Maqbool is the Founder, President, CEO and CTO of AmpliTech Group Inc. He has been in the microwave industry for over 30 years. Mr. Maqbool spent 14 years developing state-of-the-art amplifiers and components for MITEQ Inc., a leading microwave and communications equipment supplier. He founded AmpliComm in 2000, which was subsequently acquired by Aeroflex Inc. Mr. Maqbool has management and design experience, which has led to the development of microwave technology on a commercial and military level. He holds a B.S.E.E in Microwave Engineering and a B.S.E.E in Bio-Medical Engineering from CUNY and an M.S.E.E from the Polytechnic University of New York. Louisa Sanfratello is the company’s CFO. She is a Certified Public Accountant (“CPA”) and has worked in various industries since 1998. During this time, she held roles as an accountant for charities and schools, consisting of the preparation of official financial documents and day-to-day financial management requirements. Ms. Sanfratello began her professional career in 1987 at Holtz, Rubinstein & Co., a public accounting firm. She gathered two years of experience there before gaining her CPA and taking on more challenging roles. Brandon Worster is the company’s Director of Engineering. He joined AmpliTech at the end of 2019, bringing over 14 years of design and management experience. His specialty is Low Noise and Medium Power Amplifiers, but Mr. Worster also has vast experience with various systems, including RF/Microwave devices and systems. He holds a master’s degree in electrical engineering and is an adjunct professor at Farmingdale University in New York. John P. Pastore is AmpliTech’s Director of Sales. He has worked in the microwave industry for more than 35 years, including time with some of the industry’s leading names. Mr. Pastore is a hands-on professional who has experience that spans over 20 years with progressive roles that blend technical, manufacturing, customer service and management expertise. He is an extremely valuable asset to the company as it moves forward due to his business savvy approach and deep industry knowledge. He has a B.S. in Business Management.

1. Syed handles Technical Sales and is the company’s Director of IT. He is an electrical engineer with more than 10 years of business experience. Since 2011, he has led Technical Sales for AmpliTech, and he recently became the President and CEO of his own company while also serving as Chief Technical Sales consultant for numerous other companies and groups in New York City. Mr. Syed has been in the IT industry for 25 years. He is a Computer Engineer by trade and a Certified Netware Engineer and Microsoft Certified Systems Engineer.

For more information, visit the company’s website at www.AmpliTechInc.com. NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at https://ibn.fm/AMPG

• Asia Broadband Inc. announced the sales launch of the Company’s AABB Gold (“AABBG”) cryptocurrency token developed by Core State Holdings, Corp. (“CSHC”)
• The new token from AABB Wallet will be available for purchase in exchange for other major cryptocurrencies such as Bitcoin, Ethereum, and Litecoin
• The price of the AABBG token will increase or decrease, reflecting the token’s general market demand, which in turn will be influenced by the overall price of gold (the minimum token piece will increase and decrease with the price of gold, but the upside price of the token will also be influenced by market demand for the token)

Asia Broadband (OTC: AABB), is a resource company engaged in the production, supply, and sale of base and precious metals, mainly to the Asian markets.  Recently, the company announced the sales launch of the company’s AABB Gold (“AABBG”) cryptocurrency token developed by Core State Holdings, Corp. (“CSHC”).

With this launch, Asia Broadband further strengthens its position as a world leader in providing a transparent and trusted gold-backed standard of exchange by expanding token circulation targeting high growth markets globally including China and East Asia (https://ibn.fm/STzhi).

This new token from AABB Wallet will be available for purchase in exchange for other major cryptocurrencies such as Bitcoin, Ethereum, and Litecoin. Support and guide information for potential customers and users of the AABB Wallet is available on the website at www.AABBGoldToken.com, or through direct contact via the support page at https://AABBGoldToken.com/support. AABB Wallet users must update the app or download to install the latest version of the app and pass the Know Your Client (“KYC”) process to purchase the new AABB Token.

At the current market price of gold, the initial token release available for purchase is 5.4 million tokens at the one-tenth (0.1) gram of gold price (approximately USD 5.60) for each AABBG token. This token release is backed by $30 million (physical gold) the company holds. (The token is and will continue to be backed 100% by gold holdings of the company, even as additional tokens are made available for sale beyond the 5.4m initially offered for sale.) The pricing of the token works in the following manner: as the market price of gold fluctuates, the minimum supported price of the AABBG token will increase or decrease, although the potential upside price of the token will be determined by the token’s market demand.

In October last year, Asia Broadband acquired a high potential mineral property in the state of Colima, Mexico. Geophysics and groundwork have revealed significant mineralization in various segments of the Colima property. Early this year, the company announced an allocation of $10 million for the construction of exploration and development facilities and infrastructure roads on this high potential property. It’s important to note that the company intends to leverage their past production and development success in Mexico to rapidly expand and move toward production with their current projects, such as Colima.

For more information, visit the company’s website at www.AsiaBroadbandInc.com.

NOTE TO INVESTORS: The latest news and updates relating to AABB are available in the company’s newsroom at https://ibn.fm/AABB

• Nationally recognized top music lawyer Sidney (“Sid”) S. Fohrman will handle all legal aspects related to Friendable’s Fan Pass media offering
• Fan Pass has seen exponential growth since the beginning of 2021 – noting increased social media engagement
• Global livestream market is expected to reach $247.275 billion by 2027, growing at a CAGR of 28.1%
• Fan Pass expects that even with venues opening, the livestream industry will remain just as strong and continue to grow

Friendable (OTC: FDBL), a mobile technology and marketing platform focused on distributing proprietary mobile and desktop applications, has experienced exponential growth since the beginning of 2021. The company is now securing the investment and future of its fast-growing Fan Pass application, which launched in July 2020 amidst pandemic conditions, and has retained the services of Sheppard Mullin as lead counsel for all Fan Pass music, entertainment, technology, and advertising (https://ibn.fm/En7Pq). Sheppard Mullin is a multidisciplinary group but provides a full-service Entertainment and Digital Media practice led by nationally recognized top music lawyer Sidney (“Sid”) S. Fohrman. The Entertainment and Digital Media practice of Sheppard Mullin represents major motion picture studios, television networks, and other domestic and international entertainment groups in areas including:

• Music
• The development of motion picture and television
• Advertising and sweepstakes
• Production, distribution, and finance
• Licensing and merchandising
• Branded entertainment
• Convergence, online, technology, and publishing
• Intellectual property
• Esports

Fohrman has significant experience representing a diverse client base that includes private and public companies, artists, influencers, on- and off-screen talent across the entire spectrum of the entertainment industry. In addition to advising on new business models and handling licensing and content deals, sponsorships, publishing, copyright and trademark transactions, and other related aspects, Fohrman is also an experienced commercial litigator on issues such as copyright and trademark infringement, antitrust and finance, business torts, contractual disputes. “Our team continues to be blessed with relationships that strengthen our ability to grow the Fan Pass business and opportunity. The entertainment marketplace is uniquely diverse, and we are excited to have Mr. Fohrman join our team,” said Friendable CEO Robert A. Rositano Jr. “With experience and relationships that are simply unmatched in our opinion, Sid has the ability to solidify certain foundational items Fan Pass needs as we proceed with our growth strategy.” Since the beginning of 2021, Fan Pass has seen over 100% growth due to the company’s attention to metrics and feedback, continuously improving and optimizing the platform and experience for fans and artists alike. The platform is Friendable’s flagship product. I   t offers artists and fans a space to connect, providing VIP treatment without the VIP pricing. For $4.99 per month (annual pricing of $38.30 available), fans can connect and stay up to date on their favorite artists, including:

• Live performances and online concerts
• Studio sessions
• Livestreams
• Special interviews and one-on-one videos
• Behind-the-scenes footage
• Streams that highlight the artists’ daily life

The intuitive Fan Pass platform brings each artist through a streamlined onboarding process, which includes building artist “channels,” scheduling live events, and designing special edition merchandise that is offered only through Fan Pass merchandise stores. Fan Pass sign-up for artists is free, allowing them to participate in an ecosystem that embraces both the artist and the fans, connecting both in one place. Artists earn revenue from monthly fan subscriptions, merchandise sales, tickets sold for streaming events, and from content views or impressions on their channels. Each artist has a dashboard that expresses their content views and sales, including real-time payout and earnings. Since July 2020, the Fan Pass offering has grown to include artists with a pro service platform that extends the benefits provided by the company. The pro service offerings include three pricing tiers for services that accommodate artist/band logo design, merchandise design and marketing materials. At the midway point in March 2021, Fan Pass already had the momentum to surpass February figures, being ten artist sign-ups away from passing that number. Social media engagement had also increased exponentially. This rapid growth indicates that the Fan Pass model is a successful approach to supporting artists and fans in maintaining engagement in an industry heavily affected by the ongoing pandemic, positioning Friendable in a leading role in the livestreaming industry. The global livestreaming market is expected to reach $247.275 billion by 2027, growing at a CAGR of 28.1% (https://ibn.fm/jRNUg), also largely due to the pandemic. Even with venues reopening stages to artists and fans, the livestreaming industry is expected to remain strong. Fan Pass is leveraging this expectation, offering a platform with exclusive content and pay-per-view concerts that are more affordable than in-person events. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Healthy Extracts Inc. recently declared its 2020 Q4 results showing an exponential revenue increase of 71% from last year
• The company’s proprietary Fuel4Thought(TM) Brain Booster product is undergoing clinical testing, and is slated for release in Q2
• Healthy Extracts, Inc.(TM) officially changed its name from Grey Cloak Tech Inc. on March 1, 2020

Healthy Extracts (OTCQB: HYEX), is a leading researcher and manufacturer of plant-based formulations whose objective is to offer a better lifestyle through superior heart and brain health technology. The company is focused on strengthening and expanding its market reach through its science-based wholly-owned subsidiaries BergaMet North America (BergaMet NA) and Ultimate Brain Nutrients (“UBN”). In a recent announcement by Healthy Extracts, the company revealed its year-end financial reports for the year ending Dec. 31, 2020. Financial highlights of the report include revenue increases of 71% to $1,276,559 compared to 2019 revenues of $748,377. Healthy Extracts attributes its revenue boom to its adaptation of selling health-nutrition products (https://ibn.fm/Z9cjW). There has been a worldwide increase in health concerns due to the COVID-19 pandemic, greenhouse gas emissions, and the increased environmental pressure due to animal rearing. The plant-based food industry is expected to reach a value of $74.2 billion in 2027, guided by a CAGR of 11.9% from 2020 to 2027. These results are supplemented by a 2020 study by the Yale Program on Climate Change Communication, whose findings suggest that despite only 4% of the population being vegans or vegetarians, 94% of Americans are inclined towards plant-based foods (https://ibn.fm/RIx6b). Kevin Duke Pitts, Director, President, and CEO of HYEX stated that Healthy Extracts officially changed its name from Grey Cloak Tech Inc. on March 1, 2020, to reflect its business line of operations. The company currently operates through its two subsidiaries, having shut down Eqova in 2019. Healthy Extracts acquired BergaMet NA in 2019, engaged in selling and distributing a full line of proprietary product formulations derived from the rare Citrus Bergamot Superfruit(TM) (“bergamot”) native to Southern Italy. With its natural source of various antioxidant polyphenols, Bergamot has anti-inflammatory properties, reduces cholesterol, and is being touted as an effective heart health supplement. UBN develops unique, plant-based superior proprietary neuro-brain solutions that enhance the brain’s overall health. Some other business highlights for 2020 include a full reporting and upgrade to the OTCQB, the acquisition of Ultimate Brain Nutrients, and the introduction of two key products: BergaMetNA Clinical Immune and BergaMetnNA HerHeart. Clinical testings are ongoing in full-swing on the company’s proprietary Fuel4Thought Brain Booster product, which is slated for release in Q2 (https://ibn.fm/QzzJ8). For more information, visit the company’s website at www.HealthyExtractsInc.com. NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

• For more than a year, the novel coronavirus has upended society’s day-in, day-out routines and has contributed to a sense of unease nationally and worldwide
• Wide vaccine rollout and declining virus infection rates are cause for optimism about the nation’s response to COVID, but daily routines have yet to return to “normal”
• Two recent back-to-back mass-casualty shooting incidents have further threatened society’s stability and have revived debates over how to stem large-scale public violence
• Autonomous security robot (“ASR”) developer Knightscope is intent on helping to restore normalcy and greater calm through the deployment of unarmed ASR sentries that can patrol perimeters and discourage crime 24/7 without fear of falling ill or victim to violence
• A Las Vegas newspaper recently reported on a Knightscope client’s happy response to declining crime rates at an apartment complex following the ASR’s deployment last fall

History may come to regard the present years as “The COVID Era,” considering the sociological upheaval that has taken place worldwide as a result of the pandemic now stretching into its second year. The novel virus has made its presence known in all strata of society and although aggressive new vaccine rollout and declining rates of infection in many areas are generating a newfound sense of optimism, most people may yet find it difficult to remember the ease with which we once we enjoyed some basic entertainments like going to the movie theater or the city swimming pool. That difficulty was evident in the recent announcement by The Walt Disney Co. that it will delay its long-awaited superhero film “Black Widow” for a third time, but commit to finally securing its release by simultaneously making it available to home viewers on its streaming Disney+ service — a decision that dealt a blow to movie theaters hoping to begin their financial recovery from pandemic closures during the coming summer (https://ibn.fm/1WuGA). While the health crisis and vaccination efforts continue to capture primary placement in national media headlines, the idea of revolutionizing the private security guard industry may not appear as imaginative as efforts to return daily activities to “normal” but the autonomous security robot (“ASR”) innovators at Knightscope regard their mission as part and parcel of efforts to restore the well-being of the American people. “A violent crime occurs every four seconds and a property crime every 25 seconds,” Knightscope founder and CEO William Santana Li says in a recent company video biopic (https://ibn.fm/RqK1J). “Additionally the mass shooting violence across the country is not acceptable. … I don’t believe the founders of our great country ever expected that we would build a society where going to school, going to work, going shopping or to a movie literally came with a risk of being shot or killed. Crime has more than a trillion-dollar negative economic impact on the U.S. every single year.” Two mass-casualty shootings, one in Colorado and another in Georgia in less than a week’s time, are reminders that such violence and the debate over how to stave it off continue (https://ibn.fm/JPBtw). Knightscope’s response solution comes in the form of autonomous sentry robots that provide property perimeter vigilance 24 hours a day, 365 days a year. The ASRs are not weaponized defense machines like modern-day sci-fi Robocops, but they are uniquely capable of perceiving, recording and transmitting information to security personnel overseers and law enforcement while also allowing the security managers to speak immediately and directly to anyone in the ASR’s vicinity. That information may include streaming live video from a 360-degree perspective, visualizing dark and unseen areas with heat-sensing and thermal-imaging cameras, monitoring communications frequencies, and using AI to recognize targets of specific interest. One recent testimonial of the security robots’ potential to reduce crime through simple vigilance was reported this month by the Las Vegas Review-Journal, which noted that a crime-ridden apartment complex has become “a quieter, more peaceful place to live” since a Knightscope ASR was deployed there last fall. An officer with the Las Vegas Metropolitan Police Department observed the 1,129-unit apartment complex had been in the top three for 911 calls in the area, but now is no longer in the top 10, and the complex’s manager stated the ASR has deterred a lot of crime and vandalism (https://ibn.fm/Bv49z). Knightscope’s outreach team works to help ensure clients are trained in how to use the ASRs and can integrate them seamlessly into daily activity at the client property through “Post Orders” (https://ibn.fm/zTXKn). In any type of private security operation, training remains a critical requirement for ensuring the highest possible quality outcome, but unfortunately the need for ongoing, purposeful training of human security personnel may often be overlooked throughout the industry at large (https://ibn.fm/yJufp). “Long-term, I dream of building a $30 billion equivalent to a defense contractor,” Santana Li said. “Except (with a) focus on helping the U.S. Department of Homeland Security and the U.S. Department of Justice better secure our country with a wide-ranging portfolio of new ground-breaking technologies. I think it is possible.” For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• GBM is diagnosed in more than 13,000 people each year in the US, with only a 12–18-month life expectancy
• Potentially pivotal Phase 2 trial of Berubicin is scheduled to commence around the end of Q1 2021
• The company is continuing its pre-clinical work on WP1244 during 2021 and 2022
• CNS Pharmaceuticals participated in two virtual conferences during March, spreading awareness about Berubicin and the GBM indicator

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in developing novel treatments for primary and metastatic cancers of the brain and central nervous system, recently announced multiple value-driving milestones for its lead drug candidate Berubicin, a novel therapy targeting glioblastoma multiforme (“GBM”), as well as for its other drug candidate, WP1244, which targets several types of cancer (https://ibn.fm/y1XfB).

Glioblastoma Multiforme (“GBM”) is one of the most aggressive and deadly treatment-resistant cancers of the brain. GBM can affect a patient’s cognition, mood, behavior, and organ function. After diagnosis, the average life expectancy is 12-18 months resulting in close to 10,000 deaths annually in the United States. Every year, more than 13,000 new cases are diagnosed, making GBM 48% of all primary malignant brain tumors (https://ibn.fm/Z27t2).

Berubicin, one of two lead programs initially developed by Dr. Waldemar Priebe, a Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center, is a novel anthracycline that is the first anthracycline to cross the blood-brain barrier and is designed to concentrate in tumorous tissue within the brain. Berubicin is currently entering a potentially pivotal Phase 2 study for GBM treatment commencing around the end of Q1 2021. Two grant-funded studies are also scheduled to commence in Poland through WPD Pharmaceuticals, a sub-licensee partner of CNS Pharmaceuticals. The Phase 2 adult trial for GBM is expected to commence during Q2 2021 and the first-ever pediatric trial of Berubicin for malignant gliomas is expected to commence during H2 2021.

In its updated investor presentation, CNS Pharmaceuticals outlines several value-driving milestones for Berubicin that are expected to take place during 2021. These milestones include:

1. Entering three clinical trials during 2021, including the potentially pivotal Phase 2 study commencing around the end of Q1 2021
2. The interim data from WPD’s trial in Poland of Berubicin in adult GBM is expected during Q4 2021-Q1 2022
3. Multiple growth opportunities exist with the WP1244 program and the expansion into other indications

CNS Pharmaceuticals’ other drug candidate currently in development, WP1244, is a DNA-binding agent believed to be 500-times more potent than daunorubicin in inhibiting tumor cell proliferation. The current target indications for WP1244 include brain cancers, pancreatic cancers, ovarian cancers, and lymphoma. Preclinical studies show high uptake in the brain with antitumor activity. There is currently a sponsored research agreement between CNS Pharmaceuticals and The University of Texas MD Anderson Cancer Center for this drug candidate. Pre-clinical work on WP1244 will continue during 2021 and 2022.

Additionally, there is discussion of expanding Berubicin into other cancer treatment fields. The indications that are being explored include:

• Primary Brain Tumors
  • Relapsed High-Grade Gliomas – estimated population 15,000
• Brain Metastases-Combination with Radiation Therapy
  • Small Cell Lung Cancer – estimated population 56,500
  • Non-Small Cell Lung Cancer – estimated population 56,000
  • Metastatic Breast Cancer – estimated population 45,000
• CNS Lymphoma
  • Second line treatment after Methotrexate failure – estimated population 1,200

CNS Pharmaceuticals’ latest investor presentation also outlines several financial highlights. Notable achievements financially include the November 7, 2019, $9.8 million IPO, a $14 million cash balance as of December 31, 2020, and around 23.9 million shares outstanding. Based on a 10-day average of March 12, 2021, the company has a market cap around $58 million with an average volume of around 347,000.

To further advance and raise awareness of its novel therapies, CNS Pharmaceuticals attended two prominent virtual conferences in March 2021: H.C. Wainwright Global Life Sciences Conference (March 9-10) and was the inaugural Emerging Growth Virtual Conference presented by M Vest LLC and Maxim Group LLC (March 17-18). On the sidelines of the H.C. Wainwright Global Life Sciences Conference, CEO John Climaco also had the opportunity to participate in one-on-one meetings with qualified investors, while at the Emerging Growth Virtual Conference he also participated in a live glioblastoma panel discussion.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Pac Roots Cannabis recently revealed it had commenced trading on the Frankfurt Stock Exchange under symbol “4XM”
• German listing will add on to company’s existing listings on U.S. OTC market, Canadian Securities Exchange
• Pac Roots’ geographically diverse capital markets presence will allow it to cater to broader, more diverse investor audience
• Europe’s legal cannabis market expected to swell to market value of $37.1 billion by 2027

Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM), a Canada-based cannabis company dedicated towards producing premium-quality strains and products by leveraging a genetics-focused approach, announced that as of March 18, 2021, the company had commenced trading in Europe on the Frankfurt Stock Exchange under the symbol “4XM” (https://ibn.fm/AAJHd). Pac Roots will continue to be simultaneously quoted on OTC Markets under the symbol “PACRF” as well as trade on the Canadian Securities Exchange under the trading symbol “PACR.” The Frankfurt Stock Exchange listing will be a key avenue for Pac Roots to further broaden and diversify its shareholder base throughout the European Region as well as the United States. The Frankfurt Stock Exchange ranks as the largest of Germany’s seven equity bourses and as the world’s twelfth largest stock exchange by market capitalization. Furthermore, it caters to a diverse investor audience – of the approximately 200 market participants currently active on the market, approximately 50% originate from countries other than Germany. “With the cannabis industry gaining momentum in Europe, this additional listing will help increase our visibility and open doors to new investors as well as enable exciting business opportunities,” said Pac Roots President and CEO Patrick Elliott. Cannabis consumption has been increasingly decriminalized in the United States, with 34 individual states in the U.S granting consumers access to medical or recreational cannabis; however, the legalization process in Europe has lagged some way behind. European countries are scrambling to update their regulations in response to ever-increasing pressure to ease restrictions and provide an outlet for a profitable industry which is rapidly globalizing. France and Germany are currently carrying out clinical trials on the use of medical cannabis, whereas the Netherlands and Switzerland are expected to implement recreational programs by the end of the year (https://ibn.fm/jxUlU). In what may be the the biggest indication of the region’s commercial potential, Curaleaf Holdings Inc.  recently agreed to purchase privately held Emmac Life Sciences Ltd, Europe’s largest independent medical cannabis company for about $285 million, gaining access to the European Union’s medical marijuana and CBD consumer markets. The deal marked the latest iteration within the European cannabis industry’s cross-border M&A activity, with previous deals seeing the likes of Israel’s Intercure Ltd agreeing to be purchased by a U.S. SPAC and Canadian cannabis company Tilray Inc., touting its European growth plans as part of its merger with Aphria Inc. Europe’s cannabis market was recently valued at approximately $3.49 billion as of the end of 2019 (https://ibn.fm/3OASf), a mere fraction of the estimated $33.1 billion value of the legal marijuana industry in the United States this year. However, the market is estimated to swell to over $37 billion by 2027 as the pace of legalization picks up in the EU’s different member states, placing Pac Roots Cannabis in an ideal position to benefit from increased European capital market interest within the sector. For more information, visit the company’s website at www.PacRoots.ca. NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR